Tirzepatide
Tirzepatide (GLP-1/GIP Dual Receptor Agonist — Mounjaro/Zepbound)
Metabolic FDA Approved FDA: FDA-APPROVED (Mounjaro: T2DM; Zepbound...
Overview FDA-approved (Mounjaro/Zepbound). SURPASS trials: 20–22% mean weight reduction at 15 mg/week. Superior to semaglutide in head-to-head SURMOUNT-5.
Mechanism of Action Dual agonist at GLP-1R and GIPR. Synergistic dual-incretin effect. GIP action enhances insulin secretion and adipose metabolism beyond GLP-1 alone. ~5-day half-life.
Pharmacokinetics
Molecular Profile Molecular weight
4,813.55 Da
Type
Dual GLP-1/GIP agonist
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-
Key Research Findings 20–22% weight loss; superior to semaglutide (SURMOUNT-5); improved HbA1c; CV benefits.
Published Research NEJM
SURPASS-2: Tirzepatide vs Semaglutide — superior glycemic control and weight loss
View source NCBI Bookshelf
Tirzepatide StatPearls: mechanism, pharmacology, clinical use
View source Related Metabolic Compounds
Clinical Guidance
Research data is not a treatment plan. If you are considering Tirzepatide, the questions that
matter are whether it suits your history, your labs and your goals. That is a conversation with a
licensed physician, not a lookup.
Speak with a physician
LATOM Wellness is a physician-led telehealth practice. Consultation only.
No compound is sold on this site.
Running Tirzepatide? Log doses and track your cycle.
+ Add to my tracker
Educational information only. Not medical advice, and not a recommendation to use any
compound. Many compounds described here are not approved by the FDA for human use. Consult a
qualified healthcare professional before making any medical decision.All compounds · LATzoku Research